[{"data":1,"prerenderedAt":257},["ShallowReactive",2],{"$f2gcxmrdixuf45":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":54,"top_diseases":82,"top_companies":114,"key_results":142,"trends":224,"previous_editions":233,"comparison":237,"highlighted_classes":252},1,"ada-2026","ADA","ada","ADA Scientific Sessions 2026",2026,"Endocrinology & Metabolism","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2118,687,182,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 2\u002F3":4,"Phase 3":20},33,2,34,43,[22,26,30,34,37,41,45,47,50,52],{"name":23,"count":24,"share":25},"GLP1R",210,31,{"name":27,"count":28,"share":29},"INSR",111,16,{"name":31,"count":32,"share":33},"GIPR",56,8,{"name":35,"count":17,"share":36},"ND1",5,{"name":38,"count":39,"share":40},"GCGR",28,4,{"name":42,"count":43,"share":44},"SGLT2",21,3,{"name":46,"count":29,"share":18},"AMY receptor",{"name":48,"count":49,"share":4},"AMPK",9,{"name":51,"count":49,"share":4},"CALCR",{"name":53,"count":49,"share":4},"INHBE",[55,59,63,67,71,74,77,80],{"name":56,"count":57,"share":58},"Small molecules",286,42,{"name":60,"count":61,"share":62},"Peptides",248,36,{"name":64,"count":65,"share":66},"Non-antibody therapeutic proteins",167,24,{"name":68,"count":69,"share":70},"Monoclonal antibodies",51,7,{"name":72,"count":73,"share":40},"Oligonucleotide and RNA therapeutics",26,{"name":75,"count":76,"share":18},"Gene therapies",12,{"name":78,"count":79,"share":18},"Cell therapies",11,{"name":81,"count":49,"share":4},"Bispecific antibodies",[83,87,91,94,97,100,103,105,108,111],{"name":84,"count":85,"share":86},"type 2 diabetes mellitus (T2DM)",312,45,{"name":88,"count":89,"share":90},"obesity",265,39,{"name":92,"count":93,"share":29},"diabetes mellitus type 1 (T1D)",112,{"name":95,"count":96,"share":33},"insulin resistance (IR)",52,{"name":98,"count":58,"share":99},"Overweight",6,{"name":101,"count":102,"share":99},"diabetes mellitus (DM)",41,{"name":104,"count":39,"share":40},"metabolic dysfunction-associated steatotic liver disease (MASLD)",{"name":106,"count":107,"share":40},"chronic kidney disease (CKD)",27,{"name":109,"count":110,"share":44},"prediabetes",23,{"name":112,"count":113,"share":44},"hypoglycaemia",19,[115,119,123,126,129,132,134,136,138,140],{"name":116,"count":117,"share":118},"Eli Lilly",134,20,{"name":120,"count":121,"share":122},"Novo Nordisk",105,15,{"name":124,"count":125,"share":40},"Bristol Myers Squibb",30,{"name":127,"count":128,"share":18},"Pfizer",17,{"name":130,"count":131,"share":18},"Merck",13,{"name":133,"count":79,"share":18},"AstraZeneca",{"name":135,"count":79,"share":18},"Sanofi",{"name":137,"count":49,"share":4},"Bayer",{"name":139,"count":33,"share":4},"Boehringer Ingelheim",{"name":141,"count":33,"share":4},"Hanmi Pharmaceutical",[143,151,157,164,170,177,183,190,196,202,209,217],{"title":144,"drug":145,"company":147,"phase":148,"disease":84,"finding":149,"url":150},"ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5",{"name":146,"slug":146},"orforglipron",null,"Phase 3","Mean HbA1c decreased by 1.54 to 2.05% in the OFG groups vs 0.77% with PBO.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1253-or",{"title":152,"drug":153,"company":147,"phase":148,"disease":84,"finding":155,"url":156},"Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with 28-Week Open-Label Extension",{"name":154,"slug":154},"anagliptin","At week 24, HbA1c decreased 0.83% in anagliptin group versus 0.03% in placebo (difference -0.80%; 95% CI -0.95 to -0.64; P\u003C0.0001).","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1719-p",{"title":158,"drug":159,"company":147,"phase":148,"disease":84,"finding":162,"url":163},"Harmony: A Head-to-Head Phase 3 Study of HTD1801 vs. Dapagliflozin",{"name":160,"slug":161},"berberine ursodeoxycholate","berberine-ursodeoxycholate","At Week 24, HTD1801 produced an HbA1c reduction of -1.12% vs -0.93% for Dapa with a LS mean difference of -0.20% (95% CI, -0.37%, -0.03%; p\u003C0.001), confirming non-inferiority.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1781-p",{"title":165,"drug":166,"company":147,"phase":148,"disease":92,"finding":168,"url":169},"Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial",{"name":167,"slug":167},"semaglutide","In Period 1, HbA1c was reduced by 0.45% (95% CI -0.78, -0.127; p=0.0072) and body weight was reduced by 10.2 kg (95% CI -12.8, - 7.7; p\u003C0.0001) by semaglutide vs SOC.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-2876-lb",{"title":171,"drug":172,"company":147,"phase":148,"disease":174,"finding":175,"url":176},"Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial",{"name":173,"slug":173},"evolocumab","atherosclerosis","After 4.6 y median f\u002Fu, evo decreased 3-P MACE by 29% vs pbo in pts w\u002F HR-DM and 21% in those w\u002Fo HR-DM (Pint 0.47).","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1247-or",{"title":178,"drug":179,"company":147,"phase":148,"disease":84,"finding":181,"url":182},"Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial",{"name":180,"slug":180},"mazdutide","The most common adverse events were gastrointestinal (GIAEs), including nausea (30.5% with mazdutide; 12.6% with semaglutide), diarrhoea (27.0%; 21.8%), and vomiting (23.6%; 8.6%), and mostly mild to moderate in severity.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1226-or",{"title":184,"drug":185,"company":147,"phase":148,"disease":84,"finding":188,"url":189},"THDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial and Daily Glucose Control vs. Lispro (LIS) in Chinese Patients with Type 2 Diabetes (T2D)",{"name":186,"slug":187},"BioChaperone Lispro","biochaperone-lispro","Non inferiority was confirmed for the primary endpoint for BCLIS: A1C was reduced by 0.65% (BCLIS) and 0.57% (LIS): estimated treatment difference of -0.07% [95% CI -0.18; 0.03].","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1762-p",{"title":191,"drug":192,"company":147,"phase":148,"disease":92,"finding":194,"url":195},"Consistency of Glycemic Improvement with Sotagliflozin across Key Subgroups in Adults with Type 1 Diabetes: Pooled Analysis from inTandem Trials",{"name":193,"slug":193},"sotagliflozin","From a mean baseline A1C of ~7.7%, SOTA 200 mg and 400 mg significantly reduced A1C versus PBO by 0.4%.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1836-p",{"title":197,"drug":198,"company":147,"phase":148,"disease":84,"finding":200,"url":201},"Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D",{"name":199,"slug":199},"tirzepatide","The proportion of participants with hyperfiltration decreased in pooled TZP (18.6% to 5.5%) and increased in PBO (16.1% to 21.9%, p\u003C0.05, TZP vs PBO).","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1134-or",{"title":203,"drug":204,"company":147,"phase":148,"disease":206,"finding":207,"url":208},"ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b",{"name":205,"slug":205},"olezarsen","hypertriglyceridemia","Compared with placebo, the 50 mg & 80 mg doses of olezarsen reduced TGs by 57.4% (95% CI 48.6-66.2) and 64.8% (56.0-73.6) in pts with DM, respectively, and by 57.0% (45.7-68.3) and 65.1% (53.9-76.4) in pts w\u002Fo DM.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1217-or",{"title":210,"drug":211,"company":147,"phase":214,"disease":88,"finding":215,"url":216},"Efficacy and Safety of Dual GLP-1\u002FGIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial",{"name":212,"slug":212,"named_as":213},"poterepatide","HDM1005","Phase 2","HDM1005 also improved cardiometabolic parameters from baseline (difference relevant to placebo) in waist circumference (up to -7.27 cm), SBP (up to -10.19 mmHg), DBP (up to -6.13 mmHg), TG (up to -36.99%), LDL-C (up to -8.19%) and non-HDL-C (up to -11.88%).","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1034-or",{"title":218,"drug":219,"company":147,"phase":214,"disease":84,"finding":222,"url":223},"Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HDM1002) in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Diet and Exercise or Metformin",{"name":220,"slug":220,"named_as":221},"conveglipron","HDM1002","Least-squares (LS) mean changes in HbA1c for HDM1002 50, 100, 200, 400 mg QD and 200mg BID were -1.06%, -0.82%, -0.94%, -1.29% and -1.23%, respectively.","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdb26-1218-or",{"summary":225,"bullets":227},[226],"Small molecules, the most frequent modality, accounted for 42% of drug-linked abstracts, up from 37% in 2025. Oligonucleotide and RNA therapeutics accounted for 4% of drug-linked abstracts, up from 1% in 2025. Gene therapies (2%) were new to the top modalities compared with 2025.",[228,229,230,231,232],"AMY receptor (2% of drug-linked abstracts), AMPK (1%), CALCR (1%) and INHBE (1%) were new to the top targets compared with 2025.","GLP1R was the most frequent target (31%).","Type 2 diabetes mellitus (T2DM) was the most frequent disease (45%).","Eli Lilly had the largest company share (20%).","GCGR accounted for 4% of drug-linked abstracts, down from 6% in 2025.",[234],{"year":235,"abstracts":236},2025,2218,{"previous_year":235,"abstracts":238,"targets":240,"modalities":244,"new_in_top_targets":250,"new_in_top_modalities":251},{"previous":236,"current":13,"change_pct":36,"direction":239},"fell",[241,242],{"name":38,"count":39,"share":40,"previous_count":25,"previous_share":99,"direction":239},{"name":31,"count":32,"share":33,"previous_count":69,"previous_share":243,"direction":239},10,[245,249],{"name":56,"count":57,"share":58,"previous_count":246,"previous_share":247,"direction":248},196,37,"rose",{"name":72,"count":73,"share":40,"previous_count":33,"previous_share":4,"direction":248},[48,46,51,53],[75],[253],{"name":254,"count":24,"share":25,"previous_count":255,"previous_share":25,"direction":256},"GLP-1 receptor drugs",165,"flat",1793970603076]